Advertisement
LMAT vs UFPT
Which Stock Would AI Choose? LeMaitre Vascular (LMAT) vs. UFP Technologies (UFPT) Stock Comparison
Key Takeaways
- LMAT is a vascular-surgery device specialist with high gross margins and accelerating profitability, while UFPT is a contract manufacturer of single-use medical components with faster historical revenue growth.
- LMAT posted roughly 16% quarterly sales growth and sharply higher operating income, supported by price increases and product mix.
- UFPT reported record full-year revenue above $600 million, though its recent growth rate has decelerated to low-single digits as it works through production backlogs.
- LMAT carries a higher price-to-earnings multiple than UFPT, reflecting different growth and margin profiles.
- Both names operate in medical technology but with distinct business models, risk factors, and market positioning.
Introduction
Investors comparing LMAT and UFPT are weighing two very different approaches to healthcare manufacturing. LeMaitre Vascular designs and sells its own branded devices for vascular surgery, while UFP Technologies operates as a contract development and manufacturing organization, or CDMO, producing components for other medical-device makers. This stock comparison is relevant to traders and long-term investors seeking to understand how relative performance, growth drivers, and market positioning differ between a proprietary-device company and an outsourced manufacturing partner. Both companies are profitable and growing, but their momentum, margins, and risk profiles have diverged in recent market activity, making the contrast instructive for anyone evaluating small-cap medical technology.
LMAT Overview and Recent Performance
LeMaitre Vascular (LMAT) develops, manufactures, and markets disposable and implantable devices used primarily in open vascular surgery, including grafts, shunts, and valvulotomes, as well as human vascular and cardiac tissue cryopreservation services. The company sells largely to vascular surgeons through a direct sales force. In recent quarters, LMAT has demonstrated robust momentum: latest reported quarterly sales rose about 16% year over year, driven by both higher pricing and unit growth, while gross margin approached 72%. Operating income grew at a substantially faster rate than revenue, reflecting strong operating leverage.
Management has issued forward guidance pointing to continued double-digit organic sales growth, and the company has expanded shareholder returns through a higher dividend and a new share-repurchase authorization. A sizable cash position also supports potential M&A activity. Sentiment has been generally positive, though the stock trades at a premium valuation, and recent commentary has noted headwinds from a manufacturing transfer and a cybersecurity incident that management characterized as having minimal disruption.
UFPT Overview and Recent Performance
UFP Technologies (UFPT) is a designer and custom manufacturer of engineered components and packaging for medical devices, specializing in single-use and single-patient products used in minimally invasive surgery, infection prevention, wound care, and wearables. As a CDMO, its growth is tied to the product cycles of its customers, including makers of robotic-surgery systems. UFPT has reported record full-year revenue above $600 million, but its recent quarterly growth rate slowed to the low-single digits, a notable deceleration from its historically high double-digit pace.
This slowdown reflects, in part, operational inefficiencies and a customer order backlog the company is working to reduce. Operating margins have also compressed modestly versus the prior year. Analysts generally maintain a favorable view, and the company has pointed to substantial new program opportunities expected to ramp in future years. Recent relative performance has been choppy, with the stock trading well below its prior all-time high despite strong long-term returns.
Trending AI Robots
Tickeron maintains a curated page of Trending AI Robots that highlights algorithmic trading strategies currently aligned with market conditions. While Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, only a select group earns placement in this section based on recent performance, consistency, and suitability to the prevailing environment. These bots span a wide range of trading styles, strategies, timeframes, risk profiles, and ticker sets, so no single approach fits every investor. By reviewing the Trending AI Robots page, traders can explore which automated strategies are currently standing out and consider whether any align with their own objectives.
Head-to-Head Comparison
The clearest contrast between these two stocks is business model. LMAT owns its products and brand, giving it direct pricing power and exceptionally high gross margins, but exposing it to demand in the relatively niche vascular-surgery market. UFPT is an outsourced manufacturer whose fortunes depend on customer programs, giving it a more diversified revenue base but lower margins and less pricing autonomy.
In terms of growth, UFPT has historically grown revenue faster, but its momentum has cooled recently, whereas LMAT is currently posting stronger quarterly growth with expanding profitability. On valuation, LMAT trades at a higher earnings multiple than UFPT, reflecting its richer margins and steadier recent earnings trajectory. Risk profiles differ too: LMAT faces concentration risk around vascular procedures and reimbursement, while UFPT carries customer-concentration and operational-execution risk tied to specific programs. Market sentiment has favored LMAT in recent weeks, though both names remain well below their respective highs.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor LMAT in the current environment. Its combination of consistent double-digit sales growth, expanding operating margins, and clear forward guidance suggests a steadier trend than UFPT's decelerating growth and margin compression. The probability-weighted assessment leans toward LMAT on trend consistency and near-term catalysts, while acknowledging that UFPT's lower valuation and longer-term program pipeline could present a different opportunity set if execution improves. This reflects a probabilistic view of relative positioning rather than a definitive prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LMAT is a Buy and UFPT is a Hold.
LMAT in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for LMAT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LMAT as a result. In 76 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
LMAT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 229 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 167 of 235 cases where LMAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LMAT broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.642) is normal, around the industry mean (4.961). P/E Ratio (29.628) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.143). Dividend Yield (0.012) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
UFPT sees MACD Histogram just turned negative
UFPT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 09, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 39 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for UFPT moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 32 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The 10-day moving average for UFPT crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UFPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
UFPT broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 58 cases where UFPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on UFPT as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
UFPT moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where UFPT advanced for three days, in 275 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 223 of 271 cases where UFPT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. UFPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.980) is normal, around the industry mean (2.874). P/E Ratio (31.732) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (5.110) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.449) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
LMAT | UFPT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 52 | 35 | |
SMR RATING 1..100 | 52 | 52 | |
PRICE GROWTH RATING 1..100 | 60 | 38 | |
P/E GROWTH RATING 1..100 | 79 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LMAT's Valuation (74) in the Medical Specialties industry is in the same range as UFPT (92) in the Containers Or Packaging industry. This means that LMAT’s stock grew similarly to UFPT’s over the last 12 months.
UFPT's Profit vs Risk Rating (35) in the Containers Or Packaging industry is in the same range as LMAT (52) in the Medical Specialties industry. This means that UFPT’s stock grew similarly to LMAT’s over the last 12 months.
UFPT's SMR Rating (52) in the Containers Or Packaging industry is in the same range as LMAT (52) in the Medical Specialties industry. This means that UFPT’s stock grew similarly to LMAT’s over the last 12 months.
UFPT's Price Growth Rating (38) in the Containers Or Packaging industry is in the same range as LMAT (60) in the Medical Specialties industry. This means that UFPT’s stock grew similarly to LMAT’s over the last 12 months.
UFPT's P/E Growth Rating (15) in the Containers Or Packaging industry is somewhat better than the same rating for LMAT (79) in the Medical Specialties industry. This means that UFPT’s stock grew somewhat faster than LMAT’s over the last 12 months.
| LMAT | UFPT | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 64% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 83% |
| MACD ODDS (%) | N/A | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 81% |
| Advances ODDS (%) | 1 day ago 68% | 11 days ago 82% |
| Declines ODDS (%) | 21 days ago 54% | 2 days ago 70% |
| BollingerBands ODDS (%) | 1 day ago 65% | 1 day ago 65% |
| Aroon ODDS (%) | 1 day ago 71% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LMAT’s FA Score shows that 0 FA rating(s) are green while UFPT’s FA Score has 1 green FA rating(s).
- LMAT’s FA Score: 0 green, 5 red.
- UFPT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LMAT’s TA Score shows that 5 TA indicator(s) are bullish while UFPT’s TA Score has 3 bullish TA indicator(s).
- LMAT’s TA Score: 5 bullish, 3 bearish.
- UFPT’s TA Score: 3 bullish, 7 bearish.
Price Growth
LMAT (@Pharmaceuticals: Other) experienced а +2.61% price change this week, while UFPT (@Medical/Nursing Services) price change was -0.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
LMAT is expected to report earnings on Nov 04, 2026.
UFPT is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
LMAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, LMAT has been loosely correlated with ITGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LMAT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To LMAT | 1D Price Change % | ||
|---|---|---|---|---|
| LMAT | 100% | +1.98% | ||
| ITGR - LMAT | 48% Loosely correlated | -0.11% | ||
| SYK - LMAT | 46% Loosely correlated | +3.19% | ||
| UFPT - LMAT | 44% Loosely correlated | +2.49% | ||
| AORT - LMAT | 40% Loosely correlated | +4.67% | ||
| RDNT - LMAT | 39% Loosely correlated | +2.70% | ||
More | ||||
UFPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, UFPT has been loosely correlated with TCMD. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if UFPT jumps, then TCMD could also see price increases.
| Ticker / NAME | Correlation To UFPT | 1D Price Change % | ||
|---|---|---|---|---|
| UFPT | 100% | +2.49% | ||
| TCMD - UFPT | 49% Loosely correlated | +1.12% | ||
| LMAT - UFPT | 42% Loosely correlated | +1.98% | ||
| ACRS - UFPT | 39% Loosely correlated | +0.52% | ||
| ATR - UFPT | 38% Loosely correlated | +1.97% | ||
| AMIX - UFPT | 37% Loosely correlated | -2.72% | ||
More | ||||